3D 2HG mapping as biomarker for IDH-mutation in glioma
Recruiting
- Conditions
- Glioma with IDH1&2 mutationsC71Malignant neoplasm of brain
- Registration Number
- DRKS00013218
- Lead Sponsor
- Medizinische Universität Wien
- Brief Summary
FID-based 7T MRSI could not stably detect 2HG in gliomas. Indirect IDH determination based on the detectable metabolic profile seems possible and a publication is in progress as of May 2023.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
WHO grade II and III glioma according to the updated 2016 WHO classification and a Karnofsky performance status =60%
Exclusion Criteria
contraindications for MR imaging (claustrophobia, metal implants…), pregnancy
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sensitivity und specitivity of the developed MRSI methods for the measurement of 2HG and IDH status in comparison between 3 T and 7 T and to the histopathological gold standard.<br>
- Secondary Outcome Measures
Name Time Method Measurement of 2HG-concentrations during treatment at 3 T and 7 T (at least once within 6 months after glioma resection)